| Title | Mellalta Meets findings on Daiichi sankyo’s Market Positioning Strategy for DS-1062 |
|---|
| URL | https://mellalta.com/daiichi-sankyos-well-written-market-positioning-strategy-for-ds-1062-antibody-drug-conjugate-in-tnbc-and-nsclc-landscape/ |
|---|
| Category | Fitness Health --> Pharmacy |
|---|
| Meta Keywords | Non-Small Cell Lung Cancer, (NSCLC), TNBC, triple negative breast cancer, DS-1062, tumor, tumor cells, daichi sankyo’s DS-1062, Lung cancer, Breast Cancer |
|---|
| Meta Description | It’s been only a month when Daiichi Sankyo announced (pembrolizumab) in Metastatic Non-Small Cell Lung Cancer. The clinical trial has not been registered at the Clinical Trials.gov
|
|---|
| Owner | Emma Stones |
|---|
| Description |
|---|
| Daiichi Sankyo’s DS-1062 is a TROP2-directed antibody drug conjugate (ADC), designed using Daiichi Sankyo’s proprietary DXd ADC technology with the highest development stage of Phase I.
We, Mellalta Meets, unveil the Daiichi’s strategies with the our Competitive intelligence team |
